PSMA PET agents⁶⁸Ga-PSMA-11 · ¹⁸F-DCFPyL · ¹⁸F-rhPSMA
Prostate-specific membrane antigen imaging, the companion diagnostic for PSMA radioligand therapy
Quick Answer
PSMA PET agents are small-molecule urea-based inhibitors that bind the extracellular enzymatic domain of prostate-specific membrane antigen (PSMA) — a transmembrane carboxypeptidase highly overexpressed by most prostate cancers — and are then internalized, concentrating tracer in tumor. They detect disease with high sensitivity even at low PSA, and, critically, serve as the companion diagnostic that selects patients for ¹⁷⁷Lu-PSMA radioligand therapy. Common agents are ⁶⁸Ga-PSMA-11 (generator) and the fluorine-18 agents ¹⁸F-DCFPyL (piflufolastat) and ¹⁸F-rhPSMA (flotufolastat). The two interpretive keys: PSMA is not prostate-specific (celiac ganglion, healing bone, other tumors), and PSMA-low/dedifferentiated disease may need paired FDG-PET before therapy.
Mechanism
The urea-based ligands bind the extracellular catalytic (glutamate-carboxypeptidase II) domain of PSMA and, unlike a pure enzyme inhibitor, are then internalized with the receptor and retained intracellularly — giving high, durable tumor-to-background contrast. PSMA expression increases with tumor grade, stage, and androgen deprivation (castration upregulates PSMA), which is part of why detection is high in aggressive and recurrent disease. The same targeting vector delivered with a therapeutic β-emitter (Lu-177) is the basis of the theranostic pair — imaging uptake previews therapeutic delivery.
Biodistribution
Intense physiologic uptake in salivary and lacrimal glands, kidneys, and the urinary tract (renal excretion → ureteric/bladder activity); moderate uptake in liver, spleen, proximal small bowel, and celiac/sympathetic ganglia. The salivary/lacrimal avidity previews the xerostomia toxicity of PSMA therapy. ¹⁸F-rhPSMA has comparatively low urinary excretion, an advantage for evaluating the prostate bed and pelvic nodes.
Physics & Agents
| Agent | Isotope | Half-life | Production | Notes |
|---|---|---|---|---|
| ⁶⁸Ga-PSMA-11 (gozetotide) | Ga-68 | 68 min | Ge-68/Ga-68 generator | Original widely-used agent; site-flexible, batch-limited |
| ¹⁸F-DCFPyL (piflufolastat, Pylarify) | F-18 | 110 min | Cyclotron | Longer half-life, sharper images, centralized batch distribution |
| ¹⁸F-rhPSMA (flotufolastat, Posluma) | F-18 | 110 min | Cyclotron | Low urinary excretion — advantageous in the pelvis |
The shorter positron range and longer half-life of the F-18 agents support higher resolution and shipped distribution; Ga-68 needs an on-site generator but frees a center from cyclotron dependence.
Clinical Indications
- Initial staging of intermediate/high-risk prostate cancer (superior nodal and distant detection vs CT/bone scan — proPSMA).
- Biochemical recurrence — localizing disease at low PSA to direct salvage therapy.
- Companion diagnostic — confirming target expression before ¹⁷⁷Lu-PSMA and assessing response.
Preparation & Protocol
- Typical activity: ⁶⁸Ga-PSMA-11 ~1.8–2.2 MBq/kg; F-18 agents ~333 MBq (agent-specific labeling).
- Uptake time ~50–100 min (agent-dependent); hydration and voiding reduce urinary interference.
- Furosemide/hydration optional to clear ureteric activity when the pelvis is critical.
- ADT is not held — record it, since castration upregulates PSMA and raises conspicuity.
- Record the agent, uptake time, and reference-organ (blood pool/liver/parotid) uptake for PROMISE/PSMA-RADS scoring.
Interpretation Highlights
- Detection rises steeply with PSA and shorter PSA doubling time — the single most useful expectation-setting fact:
| PSA (ng/mL) | Approx. detection rate |
|---|---|
| < 0.5 | ~30–45% |
| 0.5–1.0 | ~55–65% |
| 1.0–2.0 | ~75% |
| > 2.0 | ~90%+ |
- PROMISE assigns a molecular-imaging TNM (miTNM) with uptake levels referenced to blood pool/liver/parotid; PSMA-RADS grades each lesion 1 (benign) → 5 (definite prostate cancer), separating actionable findings from those needing confirmation.
- Discordance matters: a PSMA-low but FDG-avid lesion signals dedifferentiation and predicts poorer PSMA-therapy response.
Reporting Checklist
- State agent, injected activity, uptake time, and reference-organ uptake.
- Use PROMISE (miTNM) and/or PSMA-RADS lesion-level certainty.
- Explicitly attribute physiologic/benign uptake (celiac ganglion, healing ribs, ganglia) so it is not over-called as nodal/osseous disease.
- For a therapy work-up, comment on overall PSMA expression adequacy and any PSMA-negative/FDG-discordant sites.
Common Pitfalls
- PSMA is not prostate-specific: uptake in celiac and sympathetic ganglia (mimics retrocrural/retroperitoneal nodes), healing rib fractures/Paget/fibrous dysplasia, other tumors (RCC, HCC, thyroid, glioma neovasculature), and inflammation.
- PSMA-low/negative dedifferentiated disease — false-negative for aggressive clones; pair with FDG before therapy.
- Ureteric/bladder activity obscuring the pelvis (mitigate with hydration/diuretic; rhPSMA helps).
Board Pearls
PSMA PET binds prostate-specific membrane antigen (a urea-based inhibitor of the extracellular domain, then internalized) — overexpressed by most prostate cancers and upregulated by castration/higher grade. It detects disease with high sensitivity even at low PSA (from ~30–45% at <0.5 to ~90%+ above 2.0 ng/mL, steeper with shorter doubling time) and is the companion diagnostic gating ¹⁷⁷Lu-PSMA therapy — therapy is offered only when PSMA PET confirms sufficient target expression.
PSMA is not prostate-specific. The celiac ganglion (mimicking a retrocrural node), healing ribs, Paget, fibrous dysplasia, and non-prostate tumors all take up PSMA — read pattern and anatomy, not avidity alone. Salivary/lacrimal uptake previews the xerostomia of PSMA therapy.
PSMA-low/dedifferentiated prostate cancer may be FDG-avid but PSMA-negative — pair FDG-PET before therapy when discordance is suspected, because PSMA-negative clones will not be treated by ¹⁷⁷Lu-PSMA. The F-18 agents (DCFPyL, rhPSMA) offer sharper images and shipped distribution; rhPSMA's low urinary excretion helps the pelvis; Ga-68 PSMA-11 trades resolution for generator self-sufficiency.
Related Pages
- Disease: Prostate cancer, PSMA biochemical recurrence; therapy: ¹⁷⁷Lu-PSMA-617.
- Contrast tracer: FDG (dedifferentiation phenotyping); pitfalls: Theranostics response criteria.
Figure / Diagram Suggestions
- A urea-inhibitor binding + internalization mechanism cartoon (imaging vs Lu-177 therapy).
- A PSA-vs-detection-rate curve for biochemical recurrence.
- A benign-uptake atlas (celiac ganglion, healing rib, ganglia) vs true nodal disease.
Self-Check
Q1. Why does a urea-based PSMA ligand give durable tumor retention rather than simple surface binding?
Answer: After binding the extracellular enzymatic domain, the ligand–PSMA complex is internalized and retained intracellularly, building high tumor-to-background contrast over time.
Q2. A retrocrural focus of PSMA uptake sits where a node would be but is symmetric and ganglion-shaped. What is the classic pitfall?
Answer: The celiac (sympathetic) ganglion physiologically takes up PSMA and mimics a retrocrural/retroperitoneal node — PSMA is not prostate-specific.
Q3. Before ¹⁷⁷Lu-PSMA therapy, why might you add an FDG-PET?
Answer: To detect PSMA-low/dedifferentiated but FDG-avid disease — those clones won't be treated by PSMA therapy, and discordance predicts poorer response.
Q4. At PSA 0.4 ng/mL in biochemical recurrence, what detection rate should you set expectations for, and what raises it?
Answer: Roughly 30–45%; detection rises with higher PSA and shorter PSA doubling time (to ~90%+ above 2.0 ng/mL).
Evidence & sources
https://nuc.med/psma-11/ Report an issue